Shreyashee Mallik1, Girijasankar Mallik2, Shireen Teves Macabulos3, Andrew Dorigo3. 1. Liverpool Hospital, Elizabeth Street, Liverpool, NSW, 2170, Australia. ajcmallik@gmail.com. 2. School of Business, University of Western Sydney, Sydney, Australia. 3. Palliative Care Unit, St Joseph's Hospital, Auburn, Australia.
Abstract
BACKGROUND: Hypercalcaemia is a potentially fatal paraneoplastic complication of malignancy. It primarily manifests during the advanced phase of cancer, with the life expectancy of patients ranging from weeks to months. The mainstay of treatment is with bisphosphonates, but these are not frequently used in a palliative population due to potential conflict with goals of care. GOAL: The goals of this study was to determine the reversibility of hypercalcaemia amongst patients whose underlying malignancy is not being treated and assess whether correction results in improvement in symptoms attributable to hypercalcaemia, while identifying risk factors that can predict responsiveness. METHODS: We conducted a retrospective cohort study of 63 patients aged >18 years who were admitted to the St Joseph's Palliative Care Unit, Australia between 2007 and 2013, having evidence of malignancy-associated hypercalcaemia which was treated with bisphosphonates. We assessed the response to bisphosphonates based on improvement of symptoms attributable to hypercalcaemia, as well as a reduction in serum calcium. We used the Kaplan-Meier survival method and parametric survival analysis to estimate the effect of the independent variables on time till death. RESULTS: Thirty-six of sixty three patients achieved normocalcaemia following treatment with an intravenous bisphosphonate. Complete response was influenced by the number of instances of hypercalcaemia in the past and patient factors, such as age and albumin levels. We found that a reduction in calcium level was associated with a significantly prolonged survival, as well as symptomatic improvement, irrespective of whether normocalcaemia was achieved. CONCLUSION: Our study suggests that bisphosphonates can be recommended as a palliative measure for selected patients to improve symptoms and prolong survival.
BACKGROUND:Hypercalcaemia is a potentially fatal paraneoplastic complication of malignancy. It primarily manifests during the advanced phase of cancer, with the life expectancy of patients ranging from weeks to months. The mainstay of treatment is with bisphosphonates, but these are not frequently used in a palliative population due to potential conflict with goals of care. GOAL: The goals of this study was to determine the reversibility of hypercalcaemia amongst patients whose underlying malignancy is not being treated and assess whether correction results in improvement in symptoms attributable to hypercalcaemia, while identifying risk factors that can predict responsiveness. METHODS: We conducted a retrospective cohort study of 63 patients aged >18 years who were admitted to the St Joseph's Palliative Care Unit, Australia between 2007 and 2013, having evidence of malignancy-associated hypercalcaemia which was treated with bisphosphonates. We assessed the response to bisphosphonates based on improvement of symptoms attributable to hypercalcaemia, as well as a reduction in serum calcium. We used the Kaplan-Meier survival method and parametric survival analysis to estimate the effect of the independent variables on time till death. RESULTS: Thirty-six of sixty three patients achieved normocalcaemia following treatment with an intravenous bisphosphonate. Complete response was influenced by the number of instances of hypercalcaemia in the past and patient factors, such as age and albumin levels. We found that a reduction in calcium level was associated with a significantly prolonged survival, as well as symptomatic improvement, irrespective of whether normocalcaemia was achieved. CONCLUSION: Our study suggests that bisphosphonates can be recommended as a palliative measure for selected patients to improve symptoms and prolong survival.
Authors: P Major; A Lortholary; J Hon; E Abdi; G Mills; H D Menssen; F Yunus; R Bell; J Body; E Quebe-Fehling; J Seaman Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: Ngoc Uyen Truong; Michael D deB Edwardes; Vasilios Papavasiliou; David Goltzman; Richard Kremer Journal: Am J Med Date: 2003-08-01 Impact factor: 4.965
Authors: Kerstin Kremeike; Ricarda M L Wetter; Volker Burst; Raymond Voltz; Kathrin Kuhr; Steffen T Simon Journal: Support Care Cancer Date: 2017-08-18 Impact factor: 3.603
Authors: Victoria Louise Reid; Rachael McDonald; Amara Callistus Nwosu; Stephen R Mason; Chris Probert; John E Ellershaw; Séamus Coyle Journal: PLoS One Date: 2017-04-06 Impact factor: 3.240